Pulmonary Embolism Market Grows from US$2.3 Bn to US$4.3 Bn | Persistence Market Research

Pulmonary embolism (PE), a life-threatening condition caused by the obstruction of the pulmonary artery by a blood clot, remains one of the leading causes of morbidity and mortality worldwide. The market for pulmonary embolism treatment and diagnostics has witnessed significant growth in recent years, driven by the rising incidence of venous thromboembolism (VTE), advancements in diagnostic imaging, and the growing adoption of novel therapeutic interventions. This article provides a comprehensive analysis of the pulmonary embolism market, covering market statistics, growth drivers, segmentation, regional trends, market drivers, restraints, opportunities, and competitive landscape.

Download Your Free Sample & Explore Key Insights: https://www.persistencemarketresearch.com/samples/34496

Overview of the Pulmonary Embolism Market

The global pulmonary embolism market is estimated to grow from US$ 2.3 billion in 2026 to US$ 4.3 billion by 2033, recording a compound annual growth rate (CAGR) of 9.5% during the forecast period. The market's steady growth can be attributed to several key factors, including the rising prevalence of venous thromboembolism (VTE), advancements in diagnostic techniques, and the increasing availability of effective medications and catheter-based therapies.

Key Growth Drivers Behind Market Growth

The pulmonary embolism market is experiencing robust growth due to several factors. A primary driver is the rising incidence of VTE, which includes both deep vein thrombosis (DVT) and PE. VTE is estimated to affect up to 900,000 people annually in the United States alone, with PE being one of the most common and dangerous complications. Additionally, the aging population, the rising prevalence of obesity, and an increase in cancer-related PE are contributing to the growth of the market.

Furthermore, improvements in diagnostic imaging techniques, such as Computed Tomography Pulmonary Angiography (CTPA), and the growing adoption of direct oral anticoagulants (DOACs) are propelling market expansion. The adoption of minimally invasive treatments, such as catheter-directed thrombectomy and thrombolysis, also plays a significant role in boosting market demand.

Leading Segment and Geographical Region

In terms of treatment segments, medications hold the largest share of the market, with an estimated 68.1% share in 2025. This dominance is driven by the widespread use of anticoagulants, especially DOACs like apixaban and rivaroxaban, which are preferred for their efficacy, safety profiles, and ease of administration. These medications are increasingly being prescribed in both inpatient and outpatient settings, providing a practical and effective solution for most PE patients.

Geographically, North America dominates the pulmonary embolism market, with an estimated market share of 38.0% in 2025. The region benefits from advanced healthcare infrastructure, widespread access to diagnostic tools like CTPA, strong reimbursement systems, and high levels of disease awareness. The United States, in particular, sees a significant burden of VTE cases, contributing to the demand for advanced diagnostic and therapeutic interventions. Meanwhile, Asia-Pacific is the fastest-growing region, driven by improving healthcare infrastructure, rising awareness, and increased access to diagnostic and treatment services in countries like China, India, Japan, and South Korea.

Key Highlights from the Report

• Dominant Segment: Medications account for 68.1% share of the market in 2025, driven by the use of anticoagulants and thrombolytics.
• Leading Region: North America leads the market with a 38.0% share in 2025.
• Rising Incidence: Increasing cases of venous thromboembolism and aging populations are contributing to market growth.
• Diagnostic Excellence: CT scans (CTPA) dominate PE diagnosis due to their high sensitivity and specificity.
• Therapeutic Advancements: The growth of catheter-based thrombectomy and thrombolysis is a key opportunity for the market.
• Safety Concerns: High bleeding risks associated with anticoagulants and thrombolytics limit their widespread use in PE treatment.

Market Segmentation

The pulmonary embolism market is segmented based on treatment type, diagnostic methods, and end-users, among other factors. Each of these categories plays a significant role in the overall dynamics of the market.

By Treatment Type

The treatment segment is primarily dominated by medications, which address the underlying pathophysiology of pulmonary embolism-clot formation and propagation. Anticoagulants, such as warfarin and newer direct oral anticoagulants (DOACs), are the first line of treatment for most PE cases. These medications help prevent further clotting and reduce the risk of recurrence. Thrombolytic therapies, which are used for high-risk or hemodynamically unstable PE, also contribute significantly to the market. However, the bleeding risks associated with these therapies limit their use to more critical cases.

Catheter-based interventions, including catheter-directed thrombolysis (CDT) and aspiration thrombectomy, are emerging as viable alternatives, especially in cases where anticoagulation therapy is not effective or carries high bleeding risk.

By Diagnostic Method

CT Pulmonary Angiography (CTPA) remains the gold standard for diagnosing pulmonary embolism due to its high resolution and ability to quickly and accurately identify the location of the clot in the pulmonary arteries. Other diagnostic methods, such as ventilation/perfusion scans and Doppler ultrasound, are also used but have lower sensitivity compared to CTPA.

By End-User

Hospitals and specialty clinics are the primary end-users of pulmonary embolism treatments, given the complexity of the disease and the need for specialized diagnostic and therapeutic interventions. Emergency care units, which are often the first point of contact for PE patients, also represent a significant end-user category.

Get Custom Insights Designed for Your Business: https://www.persistencemarketresearch.com/request-customization/34496

Regional Insights

North America

North America holds a significant share of the pulmonary embolism market, accounting for 38.0% of the total market in 2025. The region benefits from advanced healthcare infrastructure, with high access to diagnostic imaging tools like CT pulmonary angiography and effective anticoagulation therapies. The United States, in particular, has a high burden of VTE, which drives demand for PE-related medical interventions. The strong reimbursement systems and high levels of disease awareness further contribute to the market's growth.

Europe

Europe is another key market for pulmonary embolism treatment and diagnosis. The region is characterized by its well-established healthcare systems, extensive population base, and significant incidence of PE cases. Germany, France, and the United Kingdom are major contributors to market growth, owing to their large healthcare sectors and widespread adoption of CT scans for diagnosis. The aging population and rising cardiovascular risk factors are expected to fuel further market growth in this region.

Asia-Pacific

The Asia-Pacific region is the fastest-growing market for pulmonary embolism, driven by rapid improvements in healthcare infrastructure, increased disease awareness, and expanding access to advanced diagnostic tools and treatment modalities. Countries like China, India, and Japan are seeing a rise in VTE cases due to their large populations and increasing prevalence of lifestyle-related diseases like obesity. The growth of catheter-directed interventions and better access to anticoagulants in urban and rural settings further enhances the region's market outlook.

Market Drivers

The primary driver of the pulmonary embolism market is the rising incidence of venous thromboembolism (VTE), particularly in aging populations. As individuals age, the risk of developing conditions like PE increases, particularly in those with comorbidities like cancer and obesity. The growing use of DOACs and the adoption of minimally invasive therapies are also contributing to market growth.

Additionally, the improvements in diagnostic accuracy, especially with CTPA, and the expansion of PE response teams (PERTs) in hospitals are enhancing early detection and intervention. The growing adoption of interventional cardiology and radiology techniques, such as catheter-based thrombectomy, is opening up new treatment avenues, thus driving market expansion.

Market Restraints

Despite the promising growth, the pulmonary embolism market faces several challenges. The high bleeding risk associated with both anticoagulant and thrombolytic therapies is a significant concern. Patients with PE are often at risk of hemorrhagic complications, which can limit the use of more aggressive treatment options.

Moreover, the cost of advanced diagnostic tools like CTPA and the high cost of specialized treatments such as catheter-directed thrombectomy can be prohibitive, particularly in low- and middle-income countries. These financial barriers may restrict the widespread adoption of the most effective diagnostic and treatment options in certain regions.

Market Opportunities

The market presents several opportunities for growth. One key opportunity lies in the rapid expansion of catheter-directed thrombectomy and thrombolysis for PE, which provides a less invasive and safer alternative to systemic thrombolytic therapy. Additionally, the development of next-generation anticoagulants with better safety profiles and the growth of PE response teams (PERTs) are expected to enhance treatment outcomes and improve patient care.

Emerging markets in the Asia-Pacific region represent a significant opportunity for market expansion. With improvements in healthcare infrastructure and increased access to diagnostic and therapeutic services, countries in this region are expected to drive substantial demand for PE-related healthcare services.

Checkout Now & Download Complete Market Report: https://www.persistencemarketresearch.com/checkout/34496

Company Insights

Key Players in the Pulmonary Embolism Market

• Bayer AG
• Johnson & Johnson
• Boehringer Ingelheim
• Pfizer Inc.
• Bristol-Myers Squibb
• Amgen Inc.
• Astellas Pharma Inc.
• Daiichi Sankyo Co. Ltd.
• F. Hoffmann La Roche Ltd.
• Eli Lilly and Co.
• Gilead Sciences Inc.
• Medtronic Plc
• Inari Medical Inc.
• Novartis AG
• Sanofi
• Viatris Inc.
• Takeda Pharmaceutical Co. Ltd.

Global Pulmonary Embolism Market Segmentation

By Treatment

Surgery
Medications
Mechanical Devices
Others

By Diagnosis

MRI
CT Scan
ECG
Chest X-Ray
Pulmonary Angiography
Venous Ultrasound
Venography
D-Dimer Test
Others

By Symptom

Shortness of Breath
Cough
Chest Pain
Fever
Dizziness
Cyanosis
Irregular Heartbeat
Others

By End User

Specialty Clinics
Hospitals
Homecare
Others

By Region

North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East and Africa

Recent Developments

February 2026: Bristol Myers Squibb and Johnson & Johnson launched a clinician-focused educational initiative, "Change the Target. Change What's Possible," aimed at addressing unmet needs in cardiovascular and thromboembolic care.

January 2025: Bayer entered Phase II clinical testing for its investigational antibody BAY-3018250, aimed at enhancing clot breakdown in thrombotic cardiovascular conditions.

Conclusion

The pulmonary embolism market is poised for significant growth over the next few years, driven by increasing incidence rates, technological advancements, and the growing adoption of innovative treatments. While the market faces challenges related to safety concerns with current therapies, it also presents ample opportunities, particularly in emerging regions and with the development of new, safer therapeutic options. The market will continue to evolve as new players and products emerge, and as healthcare systems across the world improve their capacity to manage and treat pulmonary embolism effectively.

Read Related Reports:

Autoimmune Diseases Treatment Market https://www.persistencemarketresearch.com/market-research/autoimmune-diseases-treatment-market.asp
Bone Grafts Market https://www.persistencemarketresearch.com/market-research/bone-grafts-market.asp
Healthcare IT Market https://www.persistencemarketresearch.com/market-research/healthcare-it-market.asp

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.